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Background: Massively-parallel cDNA sequencing (RNA-Seq) is a new technique that holds great promise for
cardiovascular genomics. Here, we used RNA-Seq to study the transcriptomes of matched coronary artery disease
cases and controls in the ClinSeq® study, using cell lines as tissue surrogates.
Results: Lymphoblastoid cell lines (LCLs) from 16 cases and controls representing phenotypic extremes for
coronary calcification were cultured and analyzed using RNA-Seq. All cell lines were then independently re-cultured
and along with another set of 16 independent cases and controls, were profiled with Affymetrix microarrays to
perform a technical validation of the RNA-Seq results. Statistically significant changes (p < 0.05) were detected in
186 transcripts, many of which are expressed at extremely low levels (5–10 copies/cell), which we confirmed
through a separate spike-in control RNA-Seq experiment. Next, by fitting a linear model to exon-level RNA-Seq read
counts, we detected signals of alternative splicing in 18 transcripts. Finally, we used the RNA-Seq data to identify
differential expression (p < 0.0001) in eight previously unannotated regions that may represent novel transcripts. Overall,
differentially expressed genes showed strong enrichment (p = 0.0002) for prior association with cardiovascular disease.
At the network level, we found evidence for perturbation in pathways involving both cardiovascular system
development and function as well as lipid metabolism.
Conclusions: We present a pilot study for transcriptome involvement in coronary artery calcification and
demonstrate how RNA-Seq analyses using LCLs as a tissue surrogate may yield fruitful results in a clinical sequencing
project. In addition to canonical gene expression, we present candidate variants from alternative splicing and novel
transcript detection, which have been unexplored in the context of this disease.
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Coronary Artery Disease (CAD) is a leading cause of
mortality worldwide. The etiology of CAD is influenced
by lifestyle, genetics, and gut microbiome [1,2] although
the balance of these contributors remains unclear. While
numerous GWAS projects have explored the genetics of
CAD susceptibility [3], comparatively less is known
about gene expression changes in this disease [4]. This is* Correspondence: lesb@mail.nih.gov
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reproduction in any medium, provided the orpartly because CAD is a complex phenotype involving
multiple physiological systems. Consequently, no single
tissue may fully reflect the network of gene expression
changes underlying the disease [5].
In addition, current knowledge of the CAD transcriptome
is based on gene expression microarrays, a technology that
is useful but has several limitations. Recently, RNA-Seq, a
powerful new technique for transcriptome analysis has rev-
olutionized gene expression analyses by providing the abil-
ity to simultaneously interrogate all transcripts in an RNA
sample (unlike microarrays which are limited to previously
annotated transcripts) [6]. In addition, the high resolution. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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regulation that have been missed by previous technolo-
gies. Here, we present results from a pilot application of
RNA-Seq on human cases and controls chosen to reflect
extremes for coronary artery calcification (CAC), a clin-
ical marker for advanced CAD that is highly correlated
with future adverse cardiovascular events [7]. As a pa-
tient surrogate for gene expression, we used Epstein-
Barr virus transformed lymphoblastoid cell lines (LCLs),
which have been shown in multiple studies to reliably
reflect gene expression signatures [8], particularly those
associated with nearby cis-acting genomic polymorphisms
(expression quantitative trait loci or eQTLs) [9].
Here, we used RNA-Seq to compare LCLs from matched
CAC cases and controls in the ClinSeq® project [10], and
report a set of candidate genes for CAD that show dif-
ferential expression and splicing variation between the
groups, as well as novel transcripts that may have rele-
vance for disease. RNA-Seq results were experimentally
and technically replicated by repeating the cell culture
part of our experiments and then measuring gene ex-
pression independently using expression microarrays.
At the network level, we demonstrate that these dif-
ferentially expressed genes are enriched for prior CAD
association as well as for biological pathways with direct
relevance to atherosclerosis.
Methods
An expanded Methods section is provided in Additional
file 1.
Coronary calcification scoring
CAC scoring was performed using multi-slice computed
tomography (Aquilion One, Toshiba Medical Systems,
Japan or Lightspeed VCT, General Electric Healthcare,
Waukesha, Wisconsin) with the use of prospective elec-
trocardiographic gating. Calcification was quantified using
the Agatston scoring method [11] on a dedicated work-
station (VitreaFX or GE Advantage). The study was
approved by the NHGRI Institutional Review Board and
all subjects gave written informed consent.
Cell culture, RNA-Seq library preparation, and sequencing
LCLs were established by Epstein-Barr Virus (EBV) in-
oculation of B-lymphocytes using standard procedures,
grown to a density of 2–3 × 105 cells/ml, harvested
when the culture reached 107 cells in total (5–6 pas-
sages) and stored at −80°C. Total RNA from 4 × 106
cells was extracted using the RNeasy Mini kit (Qiagen).
RNA integrity was assessed using an Agilent Bioanalyzer
(Agilent). RNA-Seq libraries were constructed using a
custom protocol (see Additional file 1). Sequencing was
done on Illumina GAIIx sequencers (Illumina), collecting
two lanes of 51 bp reads for each library.RNA-Seq data processing
Reads were aligned to the human genome (hg18) using
TopHat [12]. The TopHat output SAM file was con-
verted to BED format using the bamToBed script from
the BEDTools package [13]. The coverageBed script
from BEDTools was used to count reads mapping to
individual exons in the RefSeq database (see Additional
file 1). A total count for each transcript in this database
was obtained by adding the counts for its constituent
exons. These counts, after filtering and normalization
(see Additional file 1), were used for statistical analysis
of differential expression. We confirmed the subject
identity in all RNA-Seq libraries by genotyping a subset
of expressed SNPs from the corresponding genomic
DNA. This indicated some contamination in the data for
subject 133871; hence, this subject was excluded from
further RNA-Seq analyses. The transcript-level RNA-Seq
counts were first analyzed using a two level, one-way
ANOVA to compare the expression in the case and con-
trol groups. Concurrently, the count data were analyzed
using the edgeR Bioconductor package with default set-
tings using the moderated tagwise dispersion option and
the prior. N parameter set to 4.
Affymetrix exon array experiment
For each sample, two micrograms of total RNA were
used in conjunction with the Whole-Transcript Expres-
sion Analysis protocol for Affymetrix Human Exon 1.0
ST arrays. Arrays were scanned using an Affymetrix
Gene Chip Scanner 3000 and intensities were calculated
using Affymetrix AGCC software. RMA (Robust Multi-
chip Average) signal intensities were calculated using Affy-
metrix Expression Console, converted to arithmetic scale,
and transformed using an adaptive variance-stabilizing,
quantile-normalizing transformation that was scaled to
match the transformation used on the RNA-Seq data. A
two level, one-way ANOVA was run on the microarray
expression results.
Western blot analysis of IGLL5
A small piece of human carotid atherosclerotic plaque
was frozen in liquid nitrogen and crushed to fine powder
using an alloy tool steel mortar and pestle set that was
pre-cooled in liquid nitrogen. The tissue powder was
transferred to an ice-cold microcentrifuge tube and ice-
cold cell lysis buffer (RayBiotech #0103004-L) containing
protease inhibitor cocktail (Sigma P8430) was added; the
tissue weight to buffer volume ratio was 0.1 g/0.3 ml.
The samples were vortexed for 20 seconds at 10-minute
intervals for 30 mins (and were kept on ice when not be-
ing vortexed). Samples were then centrifuged at 14000 g
for 15 minutes at 4°C; the supernatant was collected in
new microcentrifuge tubes. Protein concentrations in
the supernatant were quantified by using Micro BCA
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turer’s instructions. 50ug of protein from each sample was
separated on a 4 – 20% polyacrylamide gel (Bio-Rad, #161-
1159) with Tris-glycine – SDS buffer (Bio-Rad, #161-0732).
The proteins were transferred onto Immuno-Blot PVDF
membranes (Bio-Rad, #162-0174). The membrane was
blocked with 5% non-fat dry milk in Tris-buffered saline
Tween 20 (0.5%) for 1 hour at room temperature, then
incubated with primary antibody (anti human IGLL5,
Abgent #AP18459b) at a concentration of 1:200 over-
night at 4°C. The membranes were washed with Tris-
buffered saline Tween 20 (0.5%) three times, incubated
with a secondary peroxidase – linked antibody (anti
rabbit IgG HRP conjugate, Bio-Rad #170-6515) for two
hours at room temperature and then washed three
times with Tris-buffered saline Tween 20 (0.5%). The re-
active bands were visualized by a chemiluminescence
kit (Bio-Rad, #170-5040) on Kodak BioMax Light film.
The intensity of each IGLL5 band was analyzed by using
the Chemidoc XRS system with Western blot analysis
software (Bio-Rad). The final intensity was adjusted by in-
dividual loading control intensity readings (beta-actin).
Detection of novel transcripts
The Ensembl, AceView, ccDs, knownGenes, refGene,
tRNA and rnaGene annotation tables were downloaded
in GTF format from the UCSC Genome Browser (http://
www.genome.ucsc.edu) and combined into one master
annotation file using the Cuffmerge tool in Cufflinks
[14]. Transcripts were assembled using RNA-Seq data
from a separate LCL library with extremely high depth
of sequencing (~200 million read pairs) using Cufflinks
with the -M option to mask transcripts in the combined
annotation file. These putative novel transcripts were
then used as a reference annotation to run Cuffdiff, with
the same BAM files from the case and control subjects that
were used for quantifying gene expression. Loci detected
as significant after Benjamini-Hochberg multiple testing
correction were visually inspected by viewing the raw se-
quencing data (in BAM and BigWig format) on the UCSC
Genome Browser with all gene and gene prediction tracks
(and the ENCODE gene regulation track) turned on.
Detection of alternatively spliced transcripts
For alternative splicing, the exon-level counts were fit to
a linear mixed-effect three-factor ANOVA model con-
taining the following terms:
yijk ¼ μþ Ai þ βj ið Þ þ C þ ACik þ εijk
where y was the normalized read count for an exon, Ai
was the fixed treatment effect for 1 through i treatments
(in this case, the case or control status), βj (i) was therandom sample effect for sample j within treatment,
Ck was the fixed exon effect for 1 through k exons
within a transcript, ACik was the fixed interaction “treat-
ment X exon” effect and ε was the error factor. The
ANOVA p-value for p-AC (which indicates the strength
of the exon-treatment interaction) was then used to
select for exons showing significantly different usage
between cases and controls. Independently, the cuffdiff
algorithm [14] was also used to detect alternatively
spliced transcripts.
Results
Assessment of CAD burden and RNA-Seq experimental
design
To quantify CAD status, study subjects were assessed at
enrolment for CAC, using multi-slice computed tomog-
raphy followed by Agatston scoring (see Methods). CAC
scoring is a robust marker of CAD [15] and has been
demonstrated to be useful for both calibration and dis-
crimination of the disease burden. In addition, this
measurement of CAD also has superior positive pre-
dictive value for future adverse cardiovascular events
[16,17]. We selected eight age-, sex-, and ethnicity-
matched case:control pairs from the extremes of the cor-
onary calcium score distribution for combined RNA-Seq
and microarray analysis and another eight matched case:
control pairs for microarray-only analysis (Table 1). The
median CAC scores for cases in the first and second
groups were 1531.5 and 682.5, respectively. For compari-
son, even the presence of a CAC score (i.e., any non-zero
value) is clinically considered indicative of CAD, while a
score of 400 is often considered an advanced disease state
[17]. When the median age for the cases in the first and
second groups (56 and 61.5 years, respectively) and the
ethnicity of these subjects (Caucasian) was considered,
these scores corresponded to the 99th and 93rd centiles,
respectively, as measured using the CAC score distribu-
tion from 6110 participants in the Multi-Ethnic Study
of Atherosclerosis (MESA) [18]. This demonstrated the
severity of CAD in our discovery cases. As part of the
ClinSeq® protocol, all subjects were also analyzed using
a set of 123 clinical chemistry tests and six phenotypic
measurements (Additional file 2: Table S1). Results
from these tests did not show significant association
with calcification scores.
Analyses of gene expression with RNA-Seq data
To convert the RNA-Seq read data into a quantitative
measure of gene expression, we calculated the number
of RNA-Seq reads mapping to transcripts in the RefSeq
database (see Methods). Such transcript-level read counts
are better suited for statistical testing of gene expression
differences compared to other RNA-Seq expression
metrics [19]. Several statistical techniques have been
Table 1 Clinical data for 32 subjects
Controls Cases
ID age Calcification score ID age Calcification score
Discovery cohort (RNA-Seq +Microarray)
112916 56 0 163383 55 1114
116099 62 0 108971 63 1370
119657 53 0 198564 53 1012
133237 53 0 121424 52 514
113235 53 0 165583 53 4352
118655 58 0 189793 57 3532
119522 65 0 158592 66 2885
133871 56 0 132306 59 1693
Validation cohort (Microarray)
199039 64 0 129854 64 1268
124644 58 0 106945 58 890
199794 58 0 116106 58 697
102488 63 0 108828 64 693
184917 57 0 155489 57 672
154405 60 0 148238 61 668
117532 62 0 142361 63 654
192736 62 0 107143 62 565
All subjects were males of Caucasian ethnicity.
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RNA-Seq count data. To reduce artifacts arising from
an arbitrary choice of any single technique, we used a
dual analysis approach. First, we analyzed the count
data with the Bioconductor package edgeR [20], which
uses the negative binomial distribution to model the
count data. Using the common dispersion setting in
edgeR, we found 978 transcripts to be differentially
expressed transcripts (p < 0.05), of which 55 were
significant after applying a 5% Benjamini-Hochberg
correction for multiple testing (Figure 1A). However,
edgeR and other RNA-Seq analysis tools using the
negative binomial distribution have high rates of falseFigure 1 Volcano plots from edgeR (panel A) and ANOVA (panel B) an
logarithm of fold change (case/control). Y axis shows p value. Red dots inddiscovery [21]. To reduce artifacts arising from an
arbitrary choice of any single technique, we applied a
second, more conservative test (one-way ANOVA)
(Figure 1B) in addition to edgeR, which returned 515
transcripts at p < 0.05 without correction for multiple
testing. Overall, results from both techniques showed
good agreement, although edgeR was more liberal than
the ANOVA test in assigning low significance values. To
define a gene list, we selected transcripts that were signifi-
cant at p < 0.05 in both the edgeR and ANOVA results,
retaining 186 transcripts from 116 genes (Additional file 2:
Table S2). We noted here that neither edgeR nor ANOVA
tests were designed for isoform-level quantification; hence,alyses of RNA-Seq count data. X-axis on both panels shows base 10
icate 186 transcripts meeting p < 0.05 in both tests.
Figure 2 Plot showing RPKM values of 186 differentially
expressed transcripts and their absolute expression (measured
as copies/cell). Log10 RPKM values for controls and cases are
shown on the x and y-axes, respectively. The dashed diagonal line
represents equal RPKM values for both cases and controls, and hence
no differential expression. Thus, the orthogonal distance to the dashed
line of a point indicates the amount of differential expression. The blue
numbers on the dashed line indicate the log10 measure of copies/cell
for the seven spike-in RNA controls (ranging from 1–100000), and the
position along the x and y-axes indicate the corresponding RPKM
values recorded for these spikes. Based on a linear regression
model for copies/cell as a function of RPKM, predictions for absolute
expression measured as copies/cell for the 186 transcripts were made
from these spike-in values. For each position, the average of the RPKMs
corresponding to the x and y-coordinate values yield predictions of cell
copies based on this model and a corresponding color shown in the
background of the plot ranging from green (low) to red (high).
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we could not identify which isoform was differentially
expressed.
An interesting feature of the RNA-Seq results was that
many transcripts expressed at very low levels showed
significant differences between cases and controls. As
genes expressed at near-background levels have historic-
ally been problematic for microarray technology [22],
this aspect of the CAD transcriptome may benefit
greatly from the increased dynamic range of RNA-Seq.
To quantify absolute expression of these rare tran-
scripts, we conducted a separate RNA-Seq experiment,
starting with the same amount of total RNA used for
other experiments in this study, with the difference be-
ing that the number of cells used for RNA extraction
was precisely quantified. To the input RNA, we added
seven polyadenylated non-mammalian RNA spikes, quan-
tified such that their abundance (measured as copies per
cell) spanned five orders of magnitude (Additional file 2:
Table S3). Next, after sequencing this library to the same
depth as the others (~40 million reads), we converted
RNA-Seq reads counts of these spikes to RPKM (Reads
Per Million per Kilobase) values [19]. Finally, by compar-
ing RPKM values of differentially expressed transcripts in
our study with the spike-in control experiment, we deter-
mined that the cellular abundance of the rarer transcripts
in our data approaches ~5 copies per cell (Figure 2).
As many of the candidate genes with the highest statis-
tical significance belong to this low-expression cat-
egory (including LOC100131347 which had the lowest
p value in our ANOVA results), some observations are
relevant to note here. Firstly, before statistical testing,
we screened out transcripts which had minimal or no
coverage (see Additional file 1). Hence, these results
are unlikely to represent statistical artifacts arising
from low RNA-Seq coverage. Regarding quantity of
input material, ten micrograms of total RNA were used
for all RNA-Seq experiments, which is far above the mini-
mum requirement for the Illumina RNA-Seq protocol.
Consequently, paucity of input RNA should not cause
transcripts to appear “rare” if they are otherwise expressed
abundantly. Finally, each sample was sequenced using two
full lanes of an Illumina flow cell for a relatively high
depth of 40 million reads, which suggests that lack of
sequencing coverage would not bias our results. Overall,
these findings suggest that low-expression transcripts
(many of which may have escaped detection with previ-
ous techniques) constitute an unexplored area of the
CAD transcriptome that may contain clinically relevant
information.
Validation of RNA-Seq results using affymetrix arrays
To address the effects of variation introduced by experi-
mental procedures, we repeated the cell culture andRNA extraction steps for all 16 cell lines used for the
RNA-Seq, starting from previously frozen stocks. We
then measured gene expression in these newer cultures
using Affymetrix Human Exon 1.0 ST microarrays. Pre-
vious studies have demonstrated that these two methods
of expression measurement (RNA-Seq and microarray)
show strong agreement when applied to the same RNA
sample [23]. Here, despite the fact that two additional
passages of the cell lines took place in between the sep-
arate experiments, comparisons of the sixteen pairs of
RNA-Seq and microarray results from the same subjects
still showed high correlation (average R = 0.73, p < 0.001)
(Additional file 1: Figure S1). Hence, we conclude that
in vitro procedures did not appear to cause significant
variability in the gene expression profiles of the cell lines.
To identify gene expression differences in cases and
controls that were robust to both experimental (i.e., cell
culture) replication as well as measurement technique,
(i.e., RNA-Seq or microarray), we next selected genes
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experiments. From the list of 186 differentially expressed
transcripts found by RNA-Seq, 161 were included in the
microarray probe design. Of these, 110 were regulated in
the same direction (i.e. showed consistent upregulation
or downregulation) in both the microarray and RNA-
Seq data (Figure 3A). Given that these two gene expres-
sion measurements were conducted independently and
on different RNA extraction batches, the observed
agreement in fold change for 110/161 genes is highly
significant (one-tailed Fisher’s Exact Test, p < 0.0001;
Additional file 2: Table S4). Next, we selected a valid-
ation cohort of eight additional matched case:control
pairs from the extremes of the CAC score distribution
(Table 1) and analyzed these samples using Affymetrix
Human Exon 1.0 ST microarrays. Despite the fact that
cases in this cohort had a lower median calcification
score compared to the first cohort (682.5 and 1521.5,
respectively), we again found a significant number of
transcripts (71 of the above 110) with consistent up- or
downregulation in both cohorts (one-tailed Fisher’s Exact
Test, p = 0.0014; Figure 3B; Additional file 2: Table S5). We
conclude that these transcripts may be potential CAC
biomarkers, as their expression differences persist even
though the extent of calcification differed substantially
when comparing our first and second cohorts.
Finally, we reasoned that direct evidence of a causal rela-
tionship with CAD would be obtained if any transcriptsFigure 3 Validation of RNA-Seq results with microarray data. (A) Fold
(Y-axis) and microarrays (X-axis) in logarithm base 10 scale. Red dots show
downregulated in both experiments. (B) Comparison of microarray data fro
Red dots show 71 transcripts out of 110 in panel A that were upregulated
calculations are shown below each panel.from LCL-based analyses exhibited differential expression
patterns within actual atherosclerotic lesions. To identify
such genes, we downloaded publicly available microarray
data (GEO accession number GSE28829) from a gene
expression study of human carotid artery autopsy sam-
ples [24]. From these samples (which were part of the
Maastricht Pathology Tissue Collection), RNA was col-
lected from 13 arteries in early CAD states (pathological
intimal thickening and intimal xanthoma) and from 16 ad-
vanced CAD lesions (thin or thick fibrous cap atheroma).
The two groups of samples, which were clearly separated
by Principal Components Analysis, showed an abundance
of genes with highly significant differential expression (4039
genes with p < 0.05, one-way ANOVA test with 10%
Benjamini-Hochberg FDR correction, Additional file 1:
Figure S2). However, our aim here was not to study
these samples themselves but to identify genes showing
similar patterns in LCLs and atherosclerotic arteries. To
identify such genes, we calculated fold changes of 20639
genes that were measured in both studies (i.e. RNA-Seq
in our project and the Affymetrix U133 Plus 2.0 micro-
arrays used for the autopsy RNA study). Next, we se-
lected genes that had a fold change ≥ 1.25 in the same
direction in all three data sets (i.e. first and second sets
of CAC subjects in our study and in the CAD autopsy
samples). Two genes (MMP7 and IGLL5) met this
criterion, of which, MMP7 is especially notable due to
its functional role in atherosclerotic plaque rupturechanges (case/control) from first 16 subjects, measured by RNA-Seq
110 transcripts (out of 186 in Figure 1) that were upregulated or
m first and second groups of 16 subjects (X- and Y-axes, respectively).
or downregulated in both groups. Contingency tables for statistical
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addition, at the protein level, plasma concentrations of
MMP7 were increased in patients with coronary artery
disease [27]. Regarding IGLL5, this gene is interesting,
as apart from being upregulated with disease in two
unrelated tissues, it also had the largest fold change in
the list of 186 significant transcripts. To investigate if
IGLL5 is successfully translated in the arterial wall and
if the mRNA difference persists at the protein level, we
conducted preliminary immunoblotting experiments
on lysates from human carotid plaques. Using an anti-
human polyclonal antibody (which we confirmed to be
IGLL5-specific using siRNA knockdown experiments;
Additional file 1: Figure S3A-B), we compared three
samples each from areas exhibiting early and advanced
CAD (diffuse intimal thickening and fibroatheroma,
respectively). Corresponding to the mRNA upregula-
tion, we found a trend of increased protein levels in
lysates from advanced disease (Figure 4). IGLL5 was
also detected at abundant levels in the supernatants
of the above lysates, suggesting that it is a secreted
protein (Additional file 1: Figure S3C-D). Although the
trend of protein upregulation was not statistically sig-
nificant in this small set of samples (Additional file 2:
Table S6), given the complexity of CAD etiology, follow-









Figure 4 Immunoblot demonstrating the expression of IGLL5 in carot
area exhibiting diffuse intimal thickening (DIT). Lanes 4–6: matched lysates of
IGLL5 antibody staining. Panel B: Beta-actin band used for densitometric quan
fibroatheromatous plaques. See also Additional file 1: Figure S3 for siRNA knocAnalyses of transcription at unannotated genomic
regions
Recent evidence from RNA-Seq studies has demon-
strated that the human genome is pervasively tran-
scribed [28]. Thus, it is possible that CAD-relevant
expression differences may exist in unannotated parts
of the genome. Such differences would be even more
interesting, as previous gene expression studies of CAD
using microarrays would have entirely missed these re-
gions due to their absence in the probe design. To explore
this aspect of the transcriptome, we used the Cufflinks
suite of RNA-Seq analysis tools (see Methods) [14]. First,
we assembled novel transcripts, which we defined as those
not included in a combination of several previous annota-
tions including predicted genes. Next, we used the Cuffdiff
tool to measure differential expression in these novel
transcripts. Finally, we manually inspected the results to
confirm that they showed evidence for being putative
transcripts. Using this approach, we found eight novel
loci that show differential expression with high statis-
tical significance (p < 0.0001 after Benjamini-Hochberg
correction) (Table 2). In terms of transcript structure,
five of these eight loci contain multiple regions of in-
creased read coverage joined by spliced RNA-Seq reads
that mapped following the GT-AG rule (Figure 5). This
strongly suggested the presence of a canonical exon-
intron structure. Mapping these loci to the ENCODE3 4 5 6
ickening Fibroatheroma
id plaques obtained at endarterectomy. Lanes 1–3: lysates from an
fibroatheromatous plaque from the same samples. Panel A: anti-human
tification of IGLL5. Panel C: Increased trends of IGLL5 expression in
kdown experiments of to establish specificity of this antibody for IGLL5.
Table 2 Novel transcripts detected by Cufflinks/Cuffmerge/CuffDiff pipeline
Name Location Fold change (case/control) Corrected p value Spliced? Histone mark? EST?
CUFF.11349 chr8:101524720-101588587 −1.88185 0.041685 Yes Yes Yes
CUFF.2472 chr12:31838565-31853772 −2.26342 0.123977 Yes Yes Yes
CUFF.3 chr1:80691-80824 −11.5273 4.46E-08 No Yes Yes
CUFF.4 chr1:452495-461228 −10.6557 7.54E-10 Yes Yes Yes
CUFF.5* chr1:163653-164729 −12.5567 1.96E-10 No No Yes
CUFF.6* chr1:164811-166159 −12.8975 1.27E-12 No No No
CUFF.7* chr1:166235-166948 −12.7567 1.27E-12 Yes No Yes
CUFF.9 chr1:227665-257075 −11.1513 1.18E-08 Yes Yes Yes
Column 5 denotes presence of spliced reads following GT-AG rule. Column 6 denotes presence of layered H3K4Me1 or H3K4Me3 histone modification marks at
the locus. Column 7 denotes the presence of spliced or unspliced human ESTs in the UCSC Genome Browser database. *CUFF.5, CUFF.6 and CUFF.7 were annotated by
the Cufflinks pipeline as separate transcripts but their close location suggests that they may be components of the same transcript.
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Browser showed histone modifications indicating active
transcription. Although functional analyses will be re-
quired to confirm if these transcripts have genuine rele-
vance to CAD, these results are interesting as they form
the first description of unannotated regions of the tran-
scriptome associated with this disease. As the ability to
discover such novel transcripts is a significant advan-
tage of RNA-Seq over existing techniques, we speculate
that future analyses in different tissues and with largerFigure 5 Putative novel transcript on chromosome 12 detected by Cu
Chromosomal location. (B) WIG file showing expression levels. (C) BAM file
reverse). Segments joined by thin lines represent reads spanning a putative
absence of prior annotations for the novel transcript. (E) ENCODE enhancesample sizes will continue to demonstrate that hidden
components of CAD biology may exist outside known
genes.
Detection of candidate genes for alternative splicing
The role of alternative splicing in CAD overall (or CAC
in particular) has not been explored comprehensively,
mainly due to the difficulties of microarray platforms
in efficiently detecting changes in splicing patterns. In
contrast, RNA-Seq is extremely powerful for studyingfflinks. UCSC Genome Browser tracks in vertical order: (A)
showing mapped RNA-Seq reads (blue bars for forward strand; red for
splice junction. (D) Assorted gene and gene prediction tracks showing
r- and promoter-associated histone mark H3K4Me1.
Sen et al. BMC Genomics 2014, 15:198 Page 9 of 12
http://www.biomedcentral.com/1471-2164/15/198splicing variation. As statistical algorithms for such ana-
lyses are in an early stage of development, we chose
to proceed with a conservative approach for detecting
case:control splicing changes. Specifically, we analyzed
exon-level RNA-Seq read counts using a linear ANOVA
model fit to exon-level RNA-Seq read counts (see
Methods). This model was designed to detect genes
containing exons with increased case:control differen-
tial expression relative to other exons within the same
transcript , which would thus be potential candidates
for exon skipping, the most common form of alternative
splicing. Using this approach, we detected 45 transcripts
that show statistically significant differential usage in at
least one exon (pAC < 0.05 after 10% FDR correction)
(Figure 6). These transcripts were then validated inde-
pendently using the cuffdiff computational algorithm
[14]. Eleven transcripts were validated by both methods
and hence show promise for follow-up studies (Additional
file 2: Tables S7 and S8). Interestingly, this list included
the human leukocyte antigen gene HLA-H, variation in
which has been associated with CAD susceptibility [29].
Differentially expressed genes are enriched for CAD
association and disease-relevant functions
We next determined if differentially expressed genes
showed an overall relationship with cardiovascular dis-
ease. To investigate this, we first combined previouslyFigure 6 Examples of alternative splicing detected using exon-level a
panel). X axis shows genomic location of exons (red and black dots for ca
mean-subtracted normalized RNA-Seq read counts for each exon. Arrows
differentially expressed when all exons were considered together.compiled lists of CAD-associated genes [30,31]. From the
combined list, we identified 3424 genes which showed
expression in our RNA-Seq data. From this list, 43 genes
are present in the list of 186 differentially expressed tran-
scripts in our results. Statistically, this represented a highly
significant enrichment of CAD-associated genes (one-
tailed Fisher’s Exact Test, p = 0.0002; Additional file 1:
Figure S4), suggesting that gene expression differences
we detected by comparing cell lines from CAC cases
and controls showed an overall relationship with CAD.
At the network level, differentially expressed genes
may identify biological pathways that are perturbed in
CAD. To investigate this hypothesis, we used Ingenuity
Pathways Analysis™ (IPA) software, which performs sys-
tems biology analysis using a large repository of previ-
ously documented gene-gene interactions and functional
annotations (Additional file 3). The highest-scoring net-
work (IPA score = 48) in the list of 186 differentially
expressed transcripts included the term “Cardiovascular
System Development and Function”, further highlighting
the relationship of differential expression in this study
with CAD. Interestingly, the second highest-scoring
network (IPA score = 36) contained the function “Lipid
Metabolism”, suggesting another possible mechanism
through which gene expression differences may be related
to CAD etiology. Finally, Gene Ontology (GO) term ana-
lysis of the 186 transcripts (using only LCL-expressednalysis of RNA-Seq counts in PIGQ (top panel) and VIM (bottom
ses and controls, respectively) in hg18 coordinates. Y axis shows
at bottom right show direction of transcription. Neither gene was
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networks related to cyclic AMP metabolism (Additional
file 2: Table S9).
Discussion
We present here results from a pilot project for the use
of RNA-Seq and cell lines in studying CAC gene expres-
sion. We used gene expression microarrays and cell cul-
ture replication for technical and experimental validation,
respectively, of our initial results from this new technol-
ogy. This project should be viewed in context of its scope
and limitations; analyses of much larger numbers of LCLs
will be required before any definitive statements can be
made about the functional role in CAC of genes that we
detected. However, our primary objective in this study was
not functional analysis of such genes, but rather to identify
candidate dysregulated genes in CAC using two relatively
unexplored tools that may be useful overall in CAD re-
search. By choosing LCLs from subjects who represent
extreme outliers for the calcification score distribution,
we hypothesized that between-group differences that
are relevant for CAD may be detected. Evidence for this is
reflected in the significant enrichment of CAD-associated
genes in our results and further underscored in our IPA
results, which show that differentially expressed genes we
detected are concentrated in functional networks directly
connected to CAD. However, we do not suggest that LCLs
mirror in any way the transcriptional landscape of the
atherosclerotic lesion itself. Rather, we hypothesize that
our results represent eQTL-associated gene expression
variants, which are stably propagated in these cell lines,
underlying the observed differences between the case
and control groups. We show that the combination of
RNA-Seq and microarrays can be used to obtain useful
results with a comparatively small sample size. In the
near future, we anticipate that rapidly falling sequencing
costs and development of user-friendly data analysis
tools will soon make RNA-Seq the preferred alternative
for transcriptome studies.
As the scope of this pilot project did not include func-
tional validation assays, we refrain from speculating on
the specific mechanisms by which individual genes may
be involved in atherosclerosis development. However, as
to the best of our knowledge, this study represents the
first whole-transcriptome analysis specifically focusing
on coronary artery calcification, and differentially genes
that we found include many previous CAD candidates
(such as MMP7, EPAS1, ESAM, CASP1, GUCY1A3,
CLCN4, LEF1, ENPP5, and ZHX2), some observations
may be relevant to state here. Interestingly, we detected
differential expression of ZHX2, a regulator of plasma
lipid metabolism that is the closest gene to the top SNP
locus from a recent atherosclerosis GWAS meta-analysis
[32]. At the gene family level, the GIMAP family isenriched, with four genes (GIMAP1, GIMAP4, GIMAP5,
and GIMAP7). Perhaps not by coincidence, multiple
GIMAP family members have also been reported in a
set of 128 genes (the “A-module”) that is associated with
atherosclerosis development. Overall, the GIMAP family
has a crucial role in the development and function of T
lymphocytes, which have an important role in the etiology
of atherosclerosis [33]. Finally, it is intriguing that we de-
tected differential expression of four genes involved in
cAMP metabolism (ADM, APLP1, PRKCA and PTHLH),
as existing studies focusing on individual genes involved
in arterial calcification collectively suggest that perturb-
ation of ATP metabolism plays a role in this process [34].
Conclusions
In summary, in this project we piloted the study of cor-
onary artery calcification using cell lines as a patient sur-
rogate for gene expression. We demonstrate that with
careful experimental design and secondary validation of
results, statistically significant results can be obtained
with RNA-Seq even from a small sample size. In addition
to canonical gene expression, we focused on alternative
splicing and novel transcript discovery, two areas of the
CAD transcriptome that may benefit the most from fur-
ther RNA-Seq analyses. Studies using larger numbers of
LCLs along with follow-up experiments will be needed to
validate differentially expressed genes from this pilot study
as true CAC biomarkers; this will become possible in the
near future as we deploy RNA-Seq to the entire ClinSeq®
cohort.
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